Topical ocular delivery of fluoroquinolones

Expert Opinion on Drug Delivery

Volumn 10, Issue 5, 2013, Pages 691-711

  Pawar, Pravin ^a   Katara, Rajesh ^b   Mishra, Sushil ^b   Majumdar, Dipak K ^b  

^a CHITKARA UNIVERSITY   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Broad spectrum; Fluoroquinolones; Moxifloxacin; PKa

Indexed keywords

ALATROFLOXACIN; ALGINIC ACID; CARBOMER; CARBOPOL 940; CEFAZOLIN; CINOXACIN; CIPROFLOXACIN; ENOXACIN; FUSIDIC ACID; GATIFLOXACIN; GELLAN; GENTAMICIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLONE DERIVATIVE; RUFLOXACIN; SOLID LIPID NANOPARTICLE; SPARFLOXACIN; TOBRAMYCIN; TROVAFLOXACIN;

ACUTE DISEASE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL KERATITIS; BLEPHARITIS; CHEMOSIS; CONJUNCTIVITIS; CORNEA PERMEABILITY; CORNEA ULCER; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; DRUG SOLUTION; ENDOPHTHALMITIS; ENTEROBACTERIACEAE INFECTION; EYE TOXICITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOPHORE; PKA; PROPHYLAXIS; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; OPHTHALMIC SOLUTIONS;

EID: 84876518790     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.772977     Document Type: Article

References (121)

1. Henderer JD, Raprano CJ. Ocular pharmacology. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill, New York, USA; 2005. pp. 1707-37
2. Lemke TL, Williams DA, Rosche VF, Zito SW. editor. Foye's principles of medicinal chemistry. 6th edition. Lippincott Williams & Wilkins, Baltimore, USA; 2008
3. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83
4. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5-15 (Pubitemid 30665419)
5. Neil MJO. editor. The Merck index: An Encyclopedia of chemicals, drugs, and biologicals. 14th edition. Merck & Co Inc, Whitehouse Station, NJ, USA; 2006
6. Ross DL, Riley CM. Physicochemical properties of the fluoroquinolone antimicrobials. II. Acid ionization constants and their relationship to structure. Int J Pharm 1992;83:267-72
7. Tai MC, Lu DW,Chiang CH. Corneal and scleral permeability of quinolones -a pharmacokinetic study. J Ocul Pharmacol Ther 2003;19:547-54
8. Castillo A, Benitez del Castillo JM, Toledano N, et al. Deposits of topical norfloxacin in the treatment of bacterial keratitis. Cornea 1997;16:420-3 (Pubitemid 27282180)
9. Giannola LI, de Caro V, Giandalia G, et al. Ocular gelling microspheres: in vitro precorneal retention time and drug permeation through reconstituted corneal epithelium. J Ocul Pharmacol Ther 2008;24:186-96 (Pubitemid 351450479)
10. Rao V, Somashekar S. Preparation and Evaluation of ocular inserts containing norfloxacin. Turk J Med Sci 2004;34:239-46 (Pubitemid 39013716)
11. Alvarez-Lorenzo C, Yanez F, Barreiro-Iglesias R, Concheiro A. Imprinted soft contact lenses as norfloxacin delivery systems. J Control Release 2006;113:236-44 (Pubitemid 43963192)
12. Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Develop Technol 2011;16:44-56
13. Adenis JP, Colin J, Verin P, et al. Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: A comparison with fusidic acid. Eur J Ophthalmol 1996;6:368-74 (Pubitemid 27015935)
14. Hendrix DV, Stuffle JL, Cox SK. Pharmacokinetics of topically applied ciprofloxacin in equine tears. Vet Ophthalmol 2007;10:344-7 (Pubitemid 47631965)
15. Ozturk F, Kurt E, Inan UU, et al. The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin. Int J Pharm 2000;204:97-100
16. Dajcs JJ, Moreau JM, Thibodeaux BA, et al. Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis. Cornea 2001;20:878-80 (Pubitemid 33029490)
17. Jain D, Carvalho E, Banerjee R. Biodegradable hybrid polymeric membranes for ocular drug delivery. Acta Biomaterialia 2010;6:1370-9
18. Jain D, Carvalho E, Banthia AK, Banerjee R. Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye. Drug Dev Ind Pharm 2011;37:167-77
19. Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into anterior chamber. Nippon Ganka Gakkai Zasshi 1995;99:532-6
20. Ke TL, Cagle G, Schlech B, et al. Ocular bioavailability of ciprofloxacin in sustained release formulations. J Ocul Pharmacol Ther 2001;17:555-63 (Pubitemid 34019983)
21. Charoo NA, Kohli K, Ali A. Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies. J Pharm Sci 2003;92:407-13 (Pubitemid 36169313)
22. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv 2003;10:185-91 (Pubitemid 36993370)
23. Jain SP, Shah SP, Rajadhyaksha NS, et al. In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Dev Ind Pharm 2008;34:445-52 (Pubitemid 351519671)
24. Weyenberg W, Vermeire VA, Dhondt MM, et al. Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci 2004;45:3229-33 (Pubitemid 39121860)
25. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev Ind Pharm 2003;29:215-21 (Pubitemid 36292944)
26. Samanta A, Ghosal SK. Prolonged delivery of ciprofloxacin hydrochloride from hydrophilic ocular inserts. Acta Pol Pharm 2004;61:343-9 (Pubitemid 40188846)
27. Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm 2006;32:443-8
28. Mundada AS, Shrikhande BK. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 2008;33:469-75 (Pubitemid 351998850)
29. Budai L, Hajd-u M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm 2007;343:34-40 (Pubitemid 47334864)
30. Mehana MM, Elmaradny HA, Samala MW. Mucoadhesive liposomes as ocular delivery system: Physical, microbiological and in vivo assessment. Drug Dev Ind Pharm 2010;36:108-18
31. Martinez M, McDermott P, Walker R. Pharmacology of fluoroquinolones: A perspective for the use in domestic animals. Vet J 2006;172:10-28 (Pubitemid 43869434)
32. Cochereau-Massin I, Bauchet J, Faurisson F, et al. Ocular kinetics of pefloxacin after intramuscular administration in albino and pigmented rabbits. Antimicrob Agents Chemother 1991;35:1112-15
33. Marrakchi-Benjaafar S, Cochereau I, D'Hermies F, Pocidalo JJ. Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. Antimicrob Agents Chemother 1995;39:834-8
34. Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of Carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol. 2006;11:313-19 (Pubitemid 44221685)
35. Sultana Y, Jha MC, Ali A, Aqil M. A three-way comparative study on the efficacy of twin sol to gel systems and marketed eye drops of pefloxacin mesylate. J Ocul Pharmacol Ther 2004;20:363-71 (Pubitemid 39108901)
36. Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm 2005;55:305-14 (Pubitemid 41495274)
37. Ooshi M, Oomono A, Sakaue F, et al. Studies on intraocular penetration of. NY-198(lomefloxacin) eye drops. Acta Soc Ophthalmol Jpn 1988;11:1825-32 (Pubitemid 19016774)
38. Zhang Y, Chen Y, Chen Z. Intraocular penetration of topical lomefloxacin in rabbit's eyes. Zhonghua Yan Ke Za Zhi 1998;34:211-14
39. Velpandian T, Gupta SK, Gupta YK, et al. Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. J Ocul Pharmacol Ther 1999;15:505-11
40. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, et al. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai 2004;87:S83-90 (Pubitemid 41032725)
41. Snir M, Hasanreisoglu M, Friling R, et al. Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery. Curr Eye Res 2008;33:819-25
42. Portoles M, Iqual A, Juach A, Nos-Barbera S. In vitro toxicity of lomefloxacin in rabbit corneal epithelial cell cultures. Lens Eye Toxi Res 1990;4:469-80
43. Tian X, Iwatsu M, Kanai A. Disposable 1-day Acuvue contact lenses for the delivery of lomefloxacin to rabbits eyes. CLAO J 2001;27:212-15 (Pubitemid 33032816)
44. Ahuja M, Singh G, Majumdar DK. Effect of formulation parameters on corneal permeability of ofloxacin. Sci Pharm 2008;76:505-14
45. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 2004;273:37-44 (Pubitemid 38317038)
46. Felt O, Baeyens V, Buri P, Gurny R. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle. AAPS PharmSci 2001;3:E34
47. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001;73:205-11 (Pubitemid 32539249)
48. Di Colo G, Burgalassi S, Chetoni P, et al. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 2001;215:101-11 (Pubitemid 32206608)
49. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly (ethylene oxide). Int J Pharm 2002;48:115-22 (Pubitemid 35341415)
50. Ozturk F, Kortunay S, Kurt E, et al. The effect of long-term use and inflammation on the ocular penetration of topical ofloxacin. Curr Eye Res 1999;19:461-4 (Pubitemid 30052871)
51. Yu-Speight AW, Kern TJ, Erb HN. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. Vet Ophthalmol 2005;8:181-7 (Pubitemid 40806792)
52. Cekiç O, Batman C, Totan Y, et al. Aqueous humour levels of topically applied ciprofloxacin and ofloxacin in the same subjects. Eye 1999;13:656-9 (Pubitemid 29511841)
53. Taravella MJ, Balentine J, Young DA, Stepp P. Collagen shield delivery of ofloxacin to the human eye. J Cataract Refract Surg 1999;25:562-5 (Pubitemid 29173471)
54. De Sarro A, Zappala M, Chimirri A, et al. Quinolones potentiate cefazolin-induced seizures in DAB/2 mice. Antimicrob Agents Chemother 1993;37:1497-503 (Pubitemid 23202379)
55. Wise R, Andrews JM, Matthews R, Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992;29:649-60
56. Ghelardi E, Tavanti A, Davini P, et al. A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrob Agents Chemother 2004;48:3396-401 (Pubitemid 39129336)
57. Burgalassi S, Cappello B, Chetoni P, et al. Rufloxacin eyedrops: effect of different formulations on ocular pharmacokinetics in rabbits. Eur J Ophthalmol 2006;16:311-17 (Pubitemid 43880056)
58. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones. Am J Health Syst Pharm 1997;54:2569-84 (Pubitemid 27511865)
59. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: A therapeutic review. Clin Ther 1998;20:1049-70 (Pubitemid 29058410)
60. Gerbino PP. editor. Remington: The science and practice of pharmacy. 21st edition. Lippincott Williams & Wilkins, Philadelphia, USA; 2005
61. Ross DL, Riley CM. Aqueous solubilities of some variously substituted quinolones antimicrobials. Int J Pharm 1990;63:237-50
62. Kawazu K, Midori Y, Shiono H, Ota A. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol 1999;51:797-801 (Pubitemid 29377951)
63. Cai J, Zhang Y, Du W, Nan K. Preparation and in vitro release of spray-dried chitosan microspheres for levofloxacin delivery. J Control Release 2011;152:e70-1
64. Kawashima Y, Takahashi H, Usui M. Pharmacokinetic parameters of ofloxacin and levofloxacin ophthalmic solutions. [In Japanese] Atarsii Gannka 1995;12:791-4
65. Fukuda M, Inoue A, Sasaki K, Takahashi N. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004;48:93-6 (Pubitemid 38453779)
66. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea 2004;23:255-63 (Pubitemid 38401902)
67. Bucci Jr FA. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol 2004;137:308-12 (Pubitemid 38221005)
68. Yamada M, Mochizuki H, Yamada K, et al. Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes. J Cataract Refract Surg 2003;29:1771-5 (Pubitemid 37210615)
69. Yamada M, Ishikawa K, Mochizuki H, Kawai M. Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes. Acta Ophthalmol Scand 2006;84:192-6
70. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinilone antimicrobials. Antimicrob Agents Chemother 1998;42:1417-23 (Pubitemid 28257643)
71. Satia MC, Mody VD, Modi RI, et al. Pharmacokinetics of topically appied sparfloxacin in rabbits. Indian J Ophthalmol 2005;53:177-81 (Pubitemid 41264930)
72. Fukuda M, Sasaki K. Differences between albino and pigmented rabbit eyes in the intraocular pharmacokinetics of sparfloxacin. Drugs 1995;49:314-16
73. Cochereau-Massin I, Bauchet J, Marrakchi-Benjaafar S, et al. Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob Agents Chemother 1993;37:633-6 (Pubitemid 23096853)
74. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;39(B):1-14 (Pubitemid 27299973)
75. Barequet IS, Denton P, Osterhout GJ, et al. Treatment of experimental bacterial keratitis with topical trovafloxacin. Arch Ophthalmol 2004;122:65-9 (Pubitemid 38063607)
76. Ng EW, Joo MJ, Au Eong KG, et al. Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit. Curr Eye Res 2003;27:387-93 (Pubitemid 38019205)
77. Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 2006;7:57
78. Bristol Myers Squibb Co. New drug application for Tequin (Gatifloxacin Tablets and Injections). Environmental assessment. Center for drug evaluation and research website 2001; Available from: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2001/21-061SE2-007-Tequin-EAfonsi.pdf [Last accessed on]
79. Kaliamurthy J, Nelson Jesudasan CA, Geraldine P, et al. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res 2005;37:117-22 (Pubitemid 41022568)
80. Ozdek SC, Miller D, Flynn PM, Flynn HW. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm 2006;14:347-51 (Pubitemid 44949893)
81. Mah FS, Romanowski EG, Kowalski RP, et al. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model. Cornea 2007;26:585-8 (Pubitemid 47164718)
82. Wada T, Naka H, Tokushige H, et al. Treatment of rabbit corneal infections with ophthalmic gatifloxacin: A concentration dependence study. Adv Ther 2004;21:1-12 (Pubitemid 38649839)
83. De Castro LE, Sandoval HP, Bartholomew LR, et al. Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. J Ocul Pharmacol Ther 2006;22:132-8 (Pubitemid 43742949)
84. Wada T, Kozai S, Tajika T, et al. Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. J Ocul Pharmacol Ther 2008;24:278-89 (Pubitemid 351733228)
85. Wada T, Kida T, Inoue T, et al. Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. Ophthalmic Res 2008;40:54-60 (Pubitemid 351301283)
86. Liu Z, Li J, Nie S, et al. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315:12-17 (Pubitemid 43674115)
87. Donnenfeld RS, Perry HD, Solomon R, et al. A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model. Eye Contact Lens 2006;32:46-50 (Pubitemid 43189095)
88. Slade DS, Friday JW, Snyder RW, et al. Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. J Cataract Refract Surg 2007;33:888-92 (Pubitemid 46636201)
89. Kesavan K, Nath G, Jayanta K, Pandit JK. Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Sci Pharm 2010;78:941-57
90. Gonjari ID, Karmarkar AB, Khade TS, et al. Use of factorial design in formulation and evaluation of ophthalmic gels of gatifloxacin: comparison of different mucoadhesive polymers. Drug Discov Ther 2010;4:423-34
91. Liu Z, Yang XG, Li X, et al. Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. Drug Dev Ind Pharm 2007;33:1327-31
92. Kalam MA, Sultana Y, Samad A, et al. Gelrite based in vitro gelation ophthalmic drug delivery system of gatifloxacin. J Dispersion SciTechnol 2008;29:89-96
93. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 2008;68:513-25 (Pubitemid 351318222)
94. Kalam MA, Sultana Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Targeting 2010;18:191-204
95. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm 2010;7:576-85
96. Langlois MH, Montagut M, Dubost JP, et al. Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal 2005;37:389-93 (Pubitemid 40222313)
97. Pawar PK, Majumdar DK. Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS PharmSciTech 2006;7:E13
98. Shastri DH, Prajapati ST, Patel LD. Design and development of thermoreversible ophthalmic in situ hydrogel of moxifloxacin HCl. Curr Drug Deliv 2010;7:238-43
99. Tauber S, Cupp G, Garber R, et al. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther 2011;28:566-74
100. Nanjwade BK, Deshmukh RV, Gaikwad KR, et al. Formulation and evaluation of micro hydrogel of moxifloxacin hydrochloride. Eur J Drug Metab Pharmacokinet 2012;37:117-23
101. Pawar PK, Majumdar DK. In vitro permeation characteristics of moxifloxacin from oil drops through excised goat, sheep, buffalo and rabbit corneas. Pharmazie 2007;62:853-7 (Pubitemid 350144620)
102. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005;24:955-8
103. Hariprasad SM, Shah GK, Chi J, Prince RA. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg 2005;31:2142-6 (Pubitemid 43075382)
104. Hariprasad SM, Mieler WE, Shah GK, et al. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc 2004;102:149-55
105. Oliveira AD, D'Azevedo PA, Francisco W. In vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo. Brazil Cornea 2007;26:194-8 (Pubitemid 46168291)
106. Kim SY, Lim JA, Choi JS, et al. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007;26:720-5
107. Abshire R, Cockrum P, Crider J, Schlech B. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther 2004;26:191-6 (Pubitemid 38339011)
108. Dajcs JJ, Thibodeaux BA, Marquart ME, et al. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004;48:1948-52 (Pubitemid 38691581)
109. Thibodeaux BA, Dajcs JJ, Caballero AR, et al. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Curr Eye Res 2004;28:337-42 (Pubitemid 38638808)
110. Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 2004;138:33-7 (Pubitemid 38850246)
111. Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140:497-504
112. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: A randomized clinical trial. Ophthalmology 2007;114:1622-9 (Pubitemid 47332654)
113. Levine JM, Noecker RJ, Lane LC, et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg 2004;30:2177-82 (Pubitemid 39330678)
114. Yagci R, Oflu Y, Dinçel A, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye 2007;21:990-4 (Pubitemid 47071612)
115. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466-9 (Pubitemid 40312502)
116. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955-9 (Pubitemid 43795230)
117. Holland EJ, Lane SS, Kim T, et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 2008;27:314-19 (Pubitemid 351440866)
118. Kleinmann G, Apple DJ, Chew J, et al. Hydrophilic acrylic intraocular lens as a drug-delivery system: pilot study. J Cataract Refract Surg 2006;32:652-4
119. Kleinmann G, Larson S, Neuhann IM, et al. Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea 2006;25:209-13 (Pubitemid 43362724)
120. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112:1992-6 (Pubitemid 41551929)
121. Bucci FA, Amico LM, Evans RE. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. Eye Cont Lens 2008;34:39-42